Jeff Havenstein

8 Articles

Dividend King Johnson & Johnson Defies ‘Patent Cliff,’ Tariff Concerns

July 17, 2025

Dividend King Johnson & Johnson Defies ‘Patent Cliff,’ Tariff Concerns

JNJ shares surged after beating earnings and raising 2025 guidance. See why its new cancer drugs and Dividend King status make it a long-term buy.

Read this issue

Medtronic (MDT) Earnings and Spinoff – Should You Buy This New Robotic-Surgery Competitor?

May 23, 2025

Medtronic (MDT) Earnings and Spinoff – Should You Buy This New Robotic-Surgery Competitor?

Medtronic (MDT) posts earnings and spins off a new robotic surgery competitor. Get the key details and what investors should consider before buying.

Read this issue